ArriVent BioPharma (ArriVent BioPharma) Other Income (Expense) : $-0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Other Income (Expense)?

ArriVent BioPharma's other income expense for the ArriVent BioPharma's pretax income for the three months ended in Mar. 2024 was $-0.00 Mil. Its other income expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.00 Mil.

ArriVent BioPharma Other Income (Expense) Historical Data

The historical data trend for ArriVent BioPharma's Other Income (Expense) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Other Income (Expense) Chart

ArriVent BioPharma Annual Data

Trend

Dec21

Dec22

Dec23

Other Income (Expense)

ArriVent BioPharma Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Income (Expense)	Get a 7-Day Free Trial				-	-	-	-	-

ArriVent BioPharma Other Income (Expense) Calculation

Other income expense includes minority interest. Minority interest is a significant but non-controlling ownership of less than 50% of a company's voting shares by either an investor or another company.

Other Income (Expense) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.00 Mil.

ArriVent BioPharma (NAS:AVBP) Other Income (Expense) Explanation

Minority interest is reported on the consolidated income statement as a share of profit belonging to minority shareholders.

ArriVent BioPharma (ArriVent BioPharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Other Income (Expense)

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. They seek to utilize our team's deep drug development experience to maximize the potential of our lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.

ArriVent BioPharma (ArriVent BioPharma) Headlines

From GuruFocus

ArriVent Appoints Kristine Peterson to its Board of Directors

By Marketwired • 04-22-2024